This article is more than 5 years old. Information may no longer be current.
VIDEO: Development of tumor lysis syndrome with venetoclax leads to dose ramp-up schedule
The occurrence of tumor lysis syndrome in the clinical trial that led to approval of venetoclax for relapsed CLL with deletion of 17p has resulted in a dose ramp-up schedule for the agent, according to Ryan W. Jacobs, MD, of the Carolinas HealthCare System’s Levine Cancer Institute.
Jacobs describes the occurrence of tumor lysis syndrome during the trial and the dose ramp-up schedule that was developed. Although venetoclax (Venclexta; AbbVie, Genentech) is an oral agent, the time to initiate treatment “will be more significant” than the time needed for other kinase inhibitors used in CLL.
“The current FDA approval is now specific enough to highlight certain patient groups that will also require hospitalization as part of treatment initiation with this agent,” Jacobs said.